Abstract
Blueberries are amongst the most commonly consumed berries in the United States. Berries in general are rich in phenolic compounds, which are known for their high antioxidant capacity. Specifically, evidence from in vitro, in vivo and a few clinical studies suggest that blueberries and their active constituents show promise as effective anti-cancer agents, both in the form of functional foods and as nutritional supplements. Some of the mechanisms by which blueberries have been shown to prevent carcinogenesis include inhibition of the production of pro-inflammatory molecules, oxidative stress and products of oxidative stress such as DNA damage, inhibition of cancer cell proliferation and increased apoptosis. This review will focus on the preclinical and clinical evidence that supports blueberries as an anti-cancer fruit, as well as expressing the need for more preclinical studies and the conduction of clinical studies with respect to the cancer preventive ability of blueberries.
Keywords: Antioxidant, cancer prevention, carcinogenesis, chemoprevention, DNA damage, functional food, inflammation, oxidative stress, polyphenol, pterostilbene, tumorigenesis, vaccinium
Anti-Cancer Agents in Medicinal Chemistry
Title:Evidence for Anti-Cancer Properties of Blueberries: A Mini-Review
Volume: 13 Issue: 8
Author(s): Sarah A. Johnson and Bahram H. Arjmandi
Affiliation:
Keywords: Antioxidant, cancer prevention, carcinogenesis, chemoprevention, DNA damage, functional food, inflammation, oxidative stress, polyphenol, pterostilbene, tumorigenesis, vaccinium
Abstract: Blueberries are amongst the most commonly consumed berries in the United States. Berries in general are rich in phenolic compounds, which are known for their high antioxidant capacity. Specifically, evidence from in vitro, in vivo and a few clinical studies suggest that blueberries and their active constituents show promise as effective anti-cancer agents, both in the form of functional foods and as nutritional supplements. Some of the mechanisms by which blueberries have been shown to prevent carcinogenesis include inhibition of the production of pro-inflammatory molecules, oxidative stress and products of oxidative stress such as DNA damage, inhibition of cancer cell proliferation and increased apoptosis. This review will focus on the preclinical and clinical evidence that supports blueberries as an anti-cancer fruit, as well as expressing the need for more preclinical studies and the conduction of clinical studies with respect to the cancer preventive ability of blueberries.
Export Options
About this article
Cite this article as:
Johnson A. Sarah and Arjmandi H. Bahram, Evidence for Anti-Cancer Properties of Blueberries: A Mini-Review, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (8) . https://dx.doi.org/10.2174/18715206113139990137
DOI https://dx.doi.org/10.2174/18715206113139990137 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Reduced Lipocalin 2 Expression Contributes to Vincristine Resistance in Human Colon Cancer Cells
Recent Patents on Anti-Cancer Drug Discovery The Mechanistic Links Between Proteasome Activity, Aging and Agerelated Diseases
Current Genomics ROS-Responsive Nanomedicine: Towards Targeting the Breast Tumor Microenvironment
Current Medicinal Chemistry Clinical Application of Ghrelin
Current Pharmaceutical Design Combined Therapy for Gastrointestinal Carcinomas: Exploiting Synergies Between Gene Therapy and Classical Chemo-Radiotherapy
Current Gene Therapy Reductions in Medications with Substantial Weight Loss with Behavioral Intervention
Current Clinical Pharmacology EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Erythropoietin and Oxidative Stress
Current Neurovascular Research Suramin: Clinical Uses and Structure-Activity Relationships
Mini-Reviews in Medicinal Chemistry Inhibitors of the Immunoproteasome: Current Status and Future Directions
Current Pharmaceutical Design Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry Difference Gel Electrophoresis: Application in Quantitative Proteomics Research
Current Proteomics Functions of Polo-Like Kinases: A Journey From Yeast To Humans
Protein & Peptide Letters Molecular Dynamics in Esophageal Adenocarcinoma: Who’s in Control?
Current Cancer Drug Targets Retraction Notice: Prevention of Emetic Episodes During Cesarean Delivery Performed Under Regional Anesthesia in Parturients
Current Drug Safety Role of Polysaccharides Mimetic Components in Targeted Cancer Treatment
Current Drug Targets Endothelin Receptors in Gastrointestinal Smooth Muscle
Current Protein & Peptide Science Concomitant Expression of Inhibitory Molecules for T cell Activation Predicts Poor Survival in Patients with Esophageal Squamous Cell Carcinoma
Current Cancer Drug Targets The Targets of Curcumin
Current Drug Targets Pharmacogenetics of Estrogen Metabolism and Transport in Relation to Cancer
Current Drug Metabolism